ArticleCancer immunology, immunotherapy : CII2018
CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8
Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Diabetes exacerbates destructive inflammation by activating the CD137L-CD137 axis in dendritic and IL-17+ T cells.The Journal of clinical investigation · 2026Article
- Induction of cell death in malignant cells and regulatory T cells in the tumor microenvironment by targeting CD137.Oncoimmunology · 2025Article
- Single-cell RNA sequencing reveals the adverse role of cDC3s in the response of ulcerative colitis patients to anti-TNF-α therapy.Journal of translational medicine · 2025Article
- The roles of AIM2 in neurodegenerative diseases: insights and therapeutic implications.Frontiers in immunology · 2024Review
- Inflammasomes cross-talk with lymphocytes to connect the innate and adaptive immune response.Journal of advanced research · 2023Review
- Multimodal control of dendritic cell functions by nociceptors.Science (New York, N.Y.) · 2023Article
- Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.Cancer immunology, immunotherapy : CII · 2022Article
- CD137 costimulation is associated with reduced herpetic stromal keratitis and with developing normal CD8The Journal of general virology · 2022Article
- Immune Cell Metabolic Fitness for Life.Antibodies (Basel, Switzerland) · 2022Review
- The complex role of AIM2 in autoimmune diseases and cancers.Immunity, inflammation and disease · 2021Review
- Ectopic CD137 expression by rhabdomyosarcoma provides selection advantages but allows immunotherapeutic targeting.Oncoimmunology · 2021Article
- CD137 Ligand-CD137 Interaction is Required For Inflammasome-Associated Brain Injury Following Ischemic Stroke.Neuromolecular medicine · 2020Article
- Interleukin-1β and Cancer.Cancers · 2020Review
- The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus.Cells · 2019Review
- CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.Frontiers in immunology · 2019Review
- Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs.Frontiers in immunology · 2019Article
- Current State of Dendritic Cell-Based Immunotherapy: Opportunities forFrontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Therapeutic tumor vaccination based on dendritic cells (DC) is safe; however, its efficacy is low. Among the reasons for only a subset of patients benefitting from DC-based immunotherapy is an insufficient potency of in vitro generated classical DCs (cDCs), made by treating monocytes with GM-CSF + IL-4 + maturation factors. Recent studies demonstrated that CD137L (4-1BBL, TNFSF9) signaling differentiates human monocytes to a highly potent novel type of DC (CD137L-DCs) which have an inflammatory phenotype and are closely related to in vivo DCs. Here, we show that CD137L-DCs induce potent CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.